Contributors

Meet some of the people featured in the June 2016 issue of The Scientist.

Written byCatherine Offord
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

NORBERT VON DER GROEBENThe son of a pharmacist, Lawrence Steinman says it was only natural that he ended up pursuing a career in medicine. After earning a BA in physics from Dartmouth College in 1968, Steinman decided to devote his career to medical research and patient care. He enrolled at Harvard Medical School, where he developed a particular interest in the brain. “It’s always been the most intriguing of the organ systems,” he says, “one of the big mysteries that needs to be understood.” With a specialization in immunology, Steinman says it was another natural decision shortly after graduating in 1973 to begin work on multiple sclerosis (MS)—“the most prevalent immunological disease of the brain”—and signed on for a postdoc at the Weizmann Institute of Science in Israel. A member of Stanford University’s neurology faculty since 1980, Steinman holds numerous patents on MS treatment methods, works on the commercial development of therapeutics, and has expanded his research to consider other autoimmune diseases including diabetes. “Although my main interest has been in brain diseases, I want to solve this problem,” he says.

Steinman examines potential therapies to train the body’s defenses to tackle autoimmune disease in “Toward Targeted Therapies for Autoimmune Disorders.”

COURTESY OF RICHARD MUSCATRichard Muscat’s interest in DNA biotechnology took hold shortly after he had completed a master’s in physics at the U.K.’s University of Nottingham in 2006. “I was really fascinated by the way you can use biological components to construct things at the nanoscale,” he says. Pursing this interest through a PhD at the University of Oxford, Muscat built nanomachines from DNA molecules, while also starting to focus on “the next level” of biological engineering—synthetic biology. “Not only could you program bits of DNA to stick together,” he explains, “but you could program entire cells.” Graduating in 2011, Muscat moved to Seattle for a postdoc with Georg Seelig at the University of Washington to work on translating DNA nanotechnologies to the cell. Then, in 2015, following a brief stint working in the research division of Oxford Nanopore Technologies, he took up a position at Cancer Research UK. “I wanted to try something a bit different, but stay in science,” he says. Now working on the charity’s multidisciplinary funding scheme—set up to support collaborations between cancer researchers and other scientists, mathematicians, and engineers—Muscat says that he has enjoyed learning a new set of skills. “The fun part,” he says, “is that you’re constantly hearing about exciting new research.”

In “Synthetic Biology Comes into Its Own,” Muscat discusses the biological insights afforded by synthetic gene circuits.

JAY RUBINICJ.D. Trout credits a schoolteacher with instilling a love of philosophy at an early age. “He was teaching a lot of the classics,” Trout recalls. “Plato, Anselm’s ontological argument, existentialism—a lot of the big topics that sweep up teenagers.” After obtaining a BA in philosophy and history from Bucknell University in 1982, Trout started a PhD in the philosophy department at Cornell University. However, he soon began investigating psychology to complement his understanding of the philosophy of mind. “I couldn’t see how you could adjudicate any of the philosophical disputes without scientific knowledge of how the mind actually works,” he explains. So alongside his PhD work, Trout carried out coursework and research on speech perception in the psychology department. After graduating from Cornell in 1988, Trout spent time in several departments across the U.S. before taking up a position as a member of the philosophy faculty at Loyola University, Chicago, in 1992, where he has remained since. He has authored several books, including The Empathy Gap (2009), exploring psychological biases that influence human decisions and policy making, and continues to draw on his expertise in both philosophy and psychology. “The amount of stimulation I got in both fields just from thinking about the independent issues has been really worth it,” he says.

Trout explores the forces driving scientific progress—and the influence of “unusual accidents”—in “Start Making Sense,” an essay based on his latest book Wondrous Truths: The Improbable Triumph of Modern Science.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile

Published In

June 2016

Found in Translation

Some supposedly nonfunctional RNA molecules encode functional peptides

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies